SHARE: Simple HAART With Abacavir, Reyataz, and Epivir

Clinical Alliance for Research & Education - Infectious Diseases, LLC.

Overview

SHARE: Simple HAART with Abacavir, Reyataz, and Epivir

Open-label, multicenter study of ABC/3TC + ATV in subjects who have completed at least 24 weeks of treatment on ABC/3TC+ATV/RTV as their first line regimen and have plasma HIV-1 RNA \<50 copies/mL at entry

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Conditions

HIV Infections Lipodystrophy

Interventions

atazanavir (Reyataz)DRUG

ritonavir (Norvir)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Currently taking abacavir/lamivudine (Epzicom) in combination with atazanavir (Reyataz) boosted with ritonavir (Norvir) as first antiretroviral regimen * Viral load \<50 copies/ml Exclusion Criteria: * Viral load \>50 copies/ml * Having taken more than one antiretroviral regimen

Locations (1)

Whitman-Walker Clinic

Washington D.C., District of Columbia, United States

RECRUITING

Central Contacts

Richard A. Elion, MD

CONTACT

drrelion@aol.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.